Abiopharma

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

XWELL, Inc. Regains Nasdaq Compliance

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

New Form SCHEDULE 13G - PERRIGO Co plc Filed: 2025-08-11 AccNo: 0000093751-25-000479 Size: 8 KB

New Form 6-K - Quantum Biopharma Ltd. Filed: 2025-08-11 AccNo: 0001171843-25-005266 Size: 14 KB

BioHarvest Sciences Reports Second Quarter 2025 Financial Results

New Form 6-K - Fresenius Medical Care AG Filed: 2025-08-11 AccNo: 0001104659-25-075917 Size: 55 KB

New Form 8-K - AGENUS INC Filed: 2025-08-11 AccNo: 0000950170-25-106235 Size: 319 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Karyopharm Therapeutics Inc. Filed: 2025-08-11 AccNo: 0000950170-25-106236 Size: 487 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits